Check Out NOSI To Characterize Inborn Errors of Immunity

Funding News Edition: April 21, 2021
See more articles in this edition

Apply for funds to support the discovery and characterization of inborn errors of immunity, also known as primary immunodeficiencies, through NIAID’s Notice of Special Interest (NOSI): Investigations on Inborn Errors of Immunity/Primary Immunodeficiencies.

The NOSI’s goals are to support research leading to a deeper understanding of the causes and mechanisms of disease of inborn errors of immunity, enable early detection, and develop strategies to treat and cure these disorders.

Research Objectives and Scope

This NOSI supports investigations on primary immunodeficiencies classified by the International Union of Immunological Societies as the following:

  • Immunodeficiencies affecting cellular and humoral immunity
  • Combined immunodeficiencies with associated or syndromic features
  • Antibody deficiencies
  • Diseases of immune dysregulation
  • Congenital defects of phagocyte
  • Defects in intrinsic and innate immunity
  • Autoinflammatory disorders
  • Complement deficiencies
  • Bone marrow failure

Additionally, NIAID supports research in a wide variety of research areas, some of which are listed below. Find the full list of research areas in the NOSI linked above. 

  • Identifying the genetic basis of inborn errors of immunity
  • Characterizing the contribution of modifier genes in the pathogenesis of inborn errors of immunity
  • Developing in vitro and in vivo models to study inborn errors of immunity including models to test therapeutic strategies
  • Characterizing the factors that contribute to variable clinical penetrance associated with inborn errors of immunity
  • Developing consistent, systematic approaches to annotate inborn errors of immunity
  • Investigating genotype-phenotype correlations
  • Investigating factors responsible for age-related complications
  • Discovering/developing improved diagnostic/newborn screening tools

Nonresponsive Areas of Interest

NIAID will consider applications in the following areas to be nonresponsive:

  • Immunodeficiency resulting from infection (e.g., HIV)
  • Immunodeficiency resulting from treatments (e.g., chemotherapy), exposures (e.g., radiation), immunosuppression following transplantation, or autoimmune disorders not associated with inborn errors of immunity
  • Immunodeficiency resulting from aging or immaturity
  • Basic immunologic mechanisms unless directly related to the understanding of inborn errors of immunity

Applicants should note that this NOSI will not accept clinical trials but does encourage the use of human samples if it is within the research objectives and scope and does not involve clinical intervention.

Submission and Contact Information

This NOSI applies to due dates on or after June 5, 2021, and subsequent receipt dates through May 7, 2024. Submit applications for this initiative using one of the following funding opportunities or any reissues of these announcements through the expiration date of this notice.

  • PA-20-185, NIH Research Project Grant (Parent R01, Clinical Trial Not Allowed)
  • PA-20-195, NIH Exploratory/Developmental Research Grant Program (Parent R21, Clinical Trial Not Allowed)
  • PA-20-200, NIH Small Research Grant Program (Parent R03, Clinical Trial Not Allowed)

Applicants must follow all instructions in the SF 424 (R&R) Application Guide and include “NOT-Al-21-032” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF 424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Direct all inquiries to Dr. Frosso Voulgaropoulou, NIAID’s scientific/research contact.

Contact Us

Email us at for help navigating NIAID’s grant and contract policies and procedures.

Content last reviewed on